1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI) : a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
- 2017
- Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
- No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia : A population-based study in Sweden
- Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
- Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
- 2016
- Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli
- Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
- Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia
- In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients.
- Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.